Havent been following the story for a while. With management and board changes and cardio protection a now a big focus the FTO inhibition story is less visible to me. Can i tempt anyone to explain whether the lab/clinical trial process remains on track. Melanoma was an early target. As a bit of a tease: when i first started looking at this stock it showed promise as a cancer treatment of equal standing to standard of care in some setting but noted as being less damaging to heart. then that got de-emphasised as the FTO discovery took centre stage. Now the focus is cardio protection which feels more like the original story. I understand that cardio-protection could have broad application. But before cardio protection Wombat et al were talking about a drug that was bigger than Keytruda. Has the FTO opportunity been downgarded, pushed out delayed, seem less likely of scusses then a year ago. Has anything changed?
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-2364
-
-
- There are more pages in this discussion • 635 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.63 |
Change
-0.035(2.11%) |
Mkt cap ! $278.6M |
Open | High | Low | Value | Volume |
$1.68 | $1.68 | $1.61 | $102.2K | 62.81K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1200 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.64 | 5 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1200 | 1.630 |
1 | 35497 | 1.625 |
1 | 2300 | 1.620 |
1 | 30000 | 1.615 |
2 | 16249 | 1.610 |
Price($) | Vol. | No. |
---|---|---|
1.640 | 5 | 1 |
1.645 | 2222 | 1 |
1.650 | 1975 | 1 |
1.660 | 845 | 1 |
1.670 | 5000 | 1 |
Last trade - 13.31pm 06/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |